Endocrine Abstracts

Introduction: Pheochromocytoma and paraganglioma (PPGL) are rare endocrine tumors with few effective treatment options for malignant cases. Novel therapeutic indications, such as 177Lu-DOTA-TATE and immune checkpoint inhibitors (ICIs) for patients with PPGL, have been investigated in several clinical trials. Emerging evidence shows that somatostatin receptor 2 (SSTR2) in other cancer types correlates with the tumor microenvironment (TME) activation and could be a predictive bi...